

[News story: MHRA statement on Essure devices](#)

Advice for women following the decision by Bayer to withdraw the Essure device from the European Market.

Bayer has advised the Medicines and Healthcare products Regulatory Agency that they are withdrawing the Essure Device from the European Market.

The manufacturer has advised this is a commercial decision and is not related to any safety concerns and the device will continue to be available in the USA. They have also advised there is no need for women to have their device removed.

Patient safety is our highest priority and there is currently no evidence to suggest any increased risk to patient safety. Any women with questions should speak to their GP or healthcare professional.

We encourage any woman who has experienced a complication from her Essure device to report this to us through [the Yellow Card scheme](#), regardless of how long ago the implant was inserted.

[News story: Innovate 2017: see the best in UK innovation](#)

Some of the country's most forward-thinking businesses will showcase their products and ideas at Innovate UK's flagship event.

Almost 100 companies from across the UK will be exhibiting at [Innovate 2017](#).

If you're attending the conference as a delegate – whether that's as a start-up, investor, researcher or government official – you will get the chance to see new and novel products that are changing the world.

Wearable tech to lightweight trumpets

In total 96 organisations will take part in the innovation showcase. Innovations that will be on display include:

- [Landreez](#), a portable, eco-friendly way for people to wash their clothes when they are travelling or away from home, from Chappell Solutions

- wearable, connected technology for children that helps to keep them safe, by [Child Angel](#)
- a pet monitoring system that tracks the health, activity and behaviour of cats and dogs, by [Felcana](#)
- a lightweight hybrid trumpet that is easier for young people to use, by [Warwick Music Group](#)

Two women wear AR headsets at Innovate 2016.

Ones to watch

Other companies to look out for are:

- [Dynium Robot](#), which is developing an autonomous tractor that's of lower weight than traditional vehicles – modernising farming while reducing soil compaction. Also under development are fully electric vehicles that can perform emissions-free farming
- [HPI Technologies](#), which is developing a sensor system for use in helmets that can measure time, location and magnitude of forces to the head during impact to assist with medical interventions
- [Imagination Factory](#), which has developed its SwimAR head gear to be mounted to goggles and give swimmers access to real-time data on their performance. It includes a chronometer and lap counter
- [Lightfoot](#), which uses connected car technology to reward better driving. This should help to lower emissions and improve air quality, while making conditions safer
- [Scenic](#), which integrates with existing over-the-top video and TV and set top technology to allow friends and families in different locations to watch TV together in a virtual living room
- [The Bluespot Knee Clinic](#), which is launching its Knee Tracker. This uses gamification to encourage patients to complete their knee rehab exercises

Disruptive industries of tomorrow at Innovate 2016

[Innovate 2016 Day 2 – technologies of the future](#)

About Innovate 2017

This year's event takes place from 8 to 9 November 2017 at the [National Exhibition Centre](#) (NEC) in Birmingham.

The programme includes:

- a main stage featuring key note speakers and panel discussions on the biggest challenges and opportunities for UK innovators
- practical seminars on the Industrial Strategy Challenge Fund and other business-critical topics
- a support zone with a range of UK businesses on hand to give advice
- one-to-one brokerage sessions
- tomorrow's innovators, a new strand that's designed to inspire the next

generation

- plenty of networking opportunities

More than 2,500 people are expected to attend across the 2 days. Prices are £150 for a one-day ticket and £199 for both days.

[Press release: August 2017 Transaction Data](#)

The Transaction Data shows HM Land Registry completed 1,671,917 applications from its customers in August. This included 1,645,152 applications by account holders, of which:

1. Transaction Data is published on the 15th working day of each month. The September Transaction Data will be published at 11am on Friday 20 October 2017 at [HM Land Registry Monthly Property Transaction Data](#).
2. The monthly Transaction Data shows how many applications for first registrations, leases, transfers of part, dealings, official copies and searches lodged by HM Land Registry account customers were completed. For an explanation of the terms used, see [abbreviations used in the transaction data](#).
3. Transactions for value include freehold and leasehold sales.
4. Most searches carried out by a solicitor or conveyancer are to protect the purchase and/or mortgage. For example, a search will give the buyer priority for an application to HM Land Registry to register the purchase of the property.
5. As a government department established in 1862, executive agency and trading fund responsible to the Secretary of State for Business, Energy and Industrial Strategy, HM Land Registry keeps and maintains the Land Register for England and Wales. The Land Register has been open to public inspection since 1990.
6. With the largest transactional database of its kind detailing more than 24 million titles, HM Land Registry underpins the economy by safeguarding ownership of many billions of pounds worth of property.

7. For further information about HM Land Registry visit www.gov.uk/land-registry

8. Follow us on:

[Speech: World Alzheimer's Day: could we create a world without dementia?](#)

Could we create a world without dementia in the near future?

This is the question that for years no one has dared to ask. We assumed – wrongly – that dementia was just part of the ageing process instead of the disease of the brain it actually is. But 4 years ago that changed. The UK hosted the first ever G8 dementia summit, which set the explicit ambition to find a cure or disease-modifying therapy for dementia by 2025.

Since then, governments have formally united in the fight against dementia, and adopted the first Global Action Plan on Dementia, during the World Health Assembly in May 2017.

In the UK we have done much to improve diagnosis rates, from one of the lowest to one of the highest in Europe. This matters because an early diagnosis can support patients to make lifestyle changes that slow the progress of the disease – and also help families make adjustments to make their dementia journey easier.

Public attitudes – and specifically the stigma around dementia – are also changing. We now have over 2 million Dementia Friends, and the first dementia-friendly communities – both of them signalling a sea-change in the compassion with which we approach the disease.

And the establishment of the UK Dementia Research Institute earlier this year will provide a new focal point for research across care, prevention and technology as well as biomedical science.

We can't do this alone. Our partnership with Japan, who pioneered Dementia Friends and like us faces many challenges with an ageing population, shows how valuable cross-border collaboration is when it comes to answering one of the biggest global health challenges of our times. We have been able to ensure a continued focus on dementia throughout Japan's presidency of the G7, with learning exchanges between both nations, a successful global symposium on Building A Dementia Friendly World, and the establishment of Global Dementia Friends Ambassadors Carey Mulligan and Yuichiro Miura.

Message from Japan's Dementia Supporters Ambassador, Mr Yuichiro Miura:

[Yuichiro Miura](#).

But partnership needs to be not just between governments but with civil society and voluntary organisations as well. So we strongly support the brilliant work done by the Alzheimer's Society, Alzheimer's Research UK and other dementia-focused charities in the UK. And during the 2014 World Health Assembly, I was pleased to launch the Global Alzheimer's and Dementia Action Alliance, encouraging international NGOs to join global action against this condition.

In the end, though, our approach to dementia is quite simply a litmus test of how compassionate a society we want to be. Living with dementia can be horrific for the individual and their family – but it doesn't have to be. Social interaction – the love and support of family and friends – is one of the best possible ways to slow progression. We may not yet be able to cure the disease but we can all play a part in tackling the symptoms.

[Press release: CMA sets out scope of investment consultancy market investigation](#)

The Financial Conduct Authority (FCA) announced its [decision](#) to refer to the Competition and Markets Authority (CMA) for an in-depth market investigation on 14 September 2017.

As set out in the FCA's [terms of reference](#), the investigation covers investment consultancy services, which provide advice to institutional investors (mainly pension funds) and employers on their pension schemes; and fiduciary management services, where the provider makes and implements decisions for the investor (for example, to select a fund in which to invest).

The CMA is now carrying out a thorough and independent investigation to see if there are any market features which prevent, restrict or distort competition. If it does find competition concerns, the CMA will decide whether and – if so – what action is needed to resolve them.

The [issues statement](#) sets out a structure for the investigation, outlining potential issues and possible remedies to put in place if competition problems are found. We have grouped these in the following areas:

- whether difficulties in customers' ability to assess, compare and switch investment consultants mean investment consultants have little incentive to compete for customers
- whether conflicts of interest on the part of investment consultants reduce the quality and/or value for money of services provided to customers

- whether barriers to entry and expansion mean there are fewer challengers to put pressure on the established investment consultants to be competitive – which leads to worse outcomes for customers

The above are matters that we will be testing in our investigation. The purpose of the issues statement is to help those submitting evidence to the CMA to focus on the issues that we will investigate. We will welcome views on whether the correct issues have been identified to date and whether other issues should also be investigated, as well as views on potential remedies.

The CMA has appointed an investigation group, which will act as the decision maker in the case. This will be chaired by [John Wotton](#), one of the CMA's designated inquiry chairs. The other panel members are [Lesley Ainsworth](#), [Bob Spedding](#) and [Tim Tutton](#). All the appointees are chosen from the [CMA's expert independent panel members](#), who come from a variety of backgrounds, including economics, law, accountancy and business.

John Wotton, Chair of the Investigation Group, said:

It is extremely important that the investment consultancy sector works effectively for its clients, which include many of the UK's biggest pension funds, and we want to ensure we are looking at the right issues. That is why we are urging people to get in touch if they have any evidence to share or views about whether these are the correct areas for us to be investigating.

All information relating to the investigation will be available on the [case page](#). Submissions in response to the issues statement are invited in writing by Thursday 12 October 2017 either by email to investmentconsultants@cma.gsi.gov.uk or to:

Project Manager
Investment Consultancy Market Investigation
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

Notes for editors

1. The CMA is the UK's primary competition and consumer authority. It is an independent non-ministerial government department with responsibility for carrying out investigations into mergers, markets and the regulated industries and enforcing competition and consumer law. It has functions under the Enterprise Act 2002, as amended by the Enterprise and Regulatory Reform Act 2013.

2. In its investigation, the CMA is required to decide whether 'any feature, or combination of features, of each relevant market prevents, restricts or distorts competition in connection with the supply or acquisition of any goods or services in the United Kingdom or a part of the United Kingdom'. If so, then there is an 'adverse effect on competition' and the CMA will also consider whether there is a resulting detrimental effect on customers such as higher prices, lower quality or less choice of goods or services. The CMA will then decide whether it should put in place remedies (or recommend that other bodies should do so) to tackle the adverse effect on competition or any detrimental effect on customers so far as it has resulted from, or may be expected to result from, that adverse effect on competition, and if so, what action should be taken. If the CMA finds that there is no 'adverse effect on competition', the question of remedies will not arise.
3. Enquiries should be directed to the press@cma.gsi.gov.uk, on 020 3738 6191.
4. For more information see the CMA's [homepage](#), or follow us on Twitter [@CMAgovuk](#), [Flickr](#) and [LinkedIn](#). Sign up to our [email alerts](#) to receive updates on the markets cases.